IPN Share Price

Open 127.60 Change Price %
High 127.60 1 Day -2.85 -2.22
Low 124.80 1 Week 5.15 4.29
Close 125.30 1 Month 14.85 13.44
Volume 92560 1 Year 73.09 139.99
52 Week High 129.85
52 Week Low 50.92
IPN Important Levels
Resistance 2 127.90
Resistance 1 126.83
Pivot 125.90
Support 1 123.77
Support 2 122.70
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
MLKRI 3.43 20.77%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
ALDOL 15.00 -58.32%
MLATV 2.00 -33.33%
MLPHW 0.70 -21.35%
MLNEI 0.91 -16.51%
ALALO 0.08 -11.11%
MLAAE 4.49 -9.84%
MLHMC 3610.00 -8.38%
MLDEX 1.50 -7.41%
FED 12.55 -6.90%
FED 12.55 -6.90%
More..

Ipsen (EPA: IPN)

IPN Technical Analysis 5
As on 23rd Jun 2017 IPN Share Price closed @ 125.30 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 78.29 & Strong Buy for SHORT-TERM with Stoploss of 109.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPN Target for June
1st Target up-side 116.66
2nd Target up-side 119.76
3rd Target up-side 122.85
1st Target down-side 107.84
2nd Target down-side 104.74
3rd Target down-side 101.65
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipsen.com
IPN Address
IPN
65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
IPN Latest News
Interactive Technical Analysis Chart Ipsen ( IPN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ipsen
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.